Sapacitabine: Additional Ph III SEAMLESS data

The open-label, international Phase III SEAMLESS trial in 491 newly diagnosed AML patients ages ≥70 years who were not candidates for, or who refused, intensive induction chemotherapy showed that alternating cycles of sapacitabine and Dacogen decitabine

Read the full 369 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE